Cipla has got tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for anti-HIV/AIDS drug Slamivudine.
According to information available on the USFDA website, the tentative approval is for the oral solution of strength 10mg per ml.
The drug is in a class of medications called nucleoside reverse transcriptase inhibitors. It works by stopping the spread of the HIV and hepatitis B viruses.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
© 2025